Shots:

• Ubiquigent to receive up front- option exercise fee and milestone payment. Leo Pharma to get an option to access two novel therapies
• The partnership will strengthen Leo Pharma’s research capabilities and disease understanding and extending its expertise in medical dermatology worldwide
• The option agreement follows 2018 agreement signed b/w Ubiquigent and LEO Pharma to evaluate a collection of Ubiquigent’s novel compounds across LEO Pharma’s in-house disease-relevant assays

Click here to­ read full press release/ article | Ref: Businesswire | Image: Julia